| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8786918 | European Journal of Surgical Oncology (EJSO) | 2018 | 22 Pages |
Abstract
Intraperitoneal oxaliplatin reduced the chemoperfusion time when compared to intraperitoneal MMC without adversely influencing complication rates or short-term survival. It may therefore be the preferential drug in CRS-HIPEC procedures for colorectal PC.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
W.J. van Eden, N.F.M. Kok, K. Woensdregt, A.D.R. Huitema, H. Boot, A.G.J. Aalbers,